ahlam1399
08-12-2016, 04:25 AM
AstraZeneca wins UK cost approval for longer use of heart drug
LONDON (Reuters) - Long term use of AstraZeneca's blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain's healthcare cost watchdog NICE said on Friday.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=XyJegBqB3wQ:REiw03Ha7Zs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XyJegBqB3wQ:REiw03Ha7Zs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=XyJegBqB3wQ:REiw03Ha7Zs:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XyJegBqB3wQ:REiw03Ha7Zs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=XyJegBqB3wQ:REiw03Ha7Zs:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/XyJegBqB3wQ
LONDON (Reuters) - Long term use of AstraZeneca's blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain's healthcare cost watchdog NICE said on Friday.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=XyJegBqB3wQ:REiw03Ha7Zs:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XyJegBqB3wQ:REiw03Ha7Zs:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=XyJegBqB3wQ:REiw03Ha7Zs:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=XyJegBqB3wQ:REiw03Ha7Zs:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=XyJegBqB3wQ:REiw03Ha7Zs:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/XyJegBqB3wQ